Diamyd Medical AB DMN-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 05/10/24 CEST
0.862quote price arrow up+0.002 (+0.23%)
52 week range
0.54 - 1.72
Loading...
  • Open0.862
  • Day High0.862
  • Day Low0.862
  • Prev Close0.904
  • 52 Week High1.72
  • 52 Week High Date05/08/23
  • 52 Week Low0.54
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap98.28M
  • Shares Out94.95M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change53.65

KEY STATS

  • Open0.862
  • Day High0.862
  • Day Low0.862
  • Prev Close0.904
  • 52 Week High1.72
  • 52 Week High Date05/08/23
  • 52 Week Low0.54
  • 52 Week Low Date10/27/23
  • Market Cap98.28M
  • Shares Out94.95M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change53.65

RATIOS/PROFITABILITY

  • EPS (TTM)-0.13
  • P/E (TTM)-6.63
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Diamyd Medical AB

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of...
Anders Essen-Moeller
Independent Non-Executive Chairman of the Board
Ulf Hannelius
Chief Executive Officer
Martina Widman
Chief Operating Officer
Anna Styrud
Chief Financial Officer
Address
Kungsgatan 29
Stockholm
111 56
Sweden